Innate Pharma (IPHA) Accounts Payables (2017 - 2025)

Innate Pharma has reported Accounts Payables for 9 years, with the latest figure at $17.5 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 2.37% year-over-year to $17.5 million; the trailing twelve-month figure through Dec 2025 stood at $17.5 million (up 2.37% YoY), and the FY2025 full-year result was $17.5 million, up 2.37% from the prior year.
• Accounts Payables for Q4 2025 stood at $17.5 million, up from $13.6 million in the prior quarter.
• The five-year high for Accounts Payables was $32.7 million in Q4 2021, with the low at $13.6 million in Q2 2025.
• Historically, Accounts Payables has averaged $19.9 million across 5 years, with a median of $19.1 million in 2022.
• Annual changes were most pronounced in 2021 — Accounts Payables plunged 99.92% — and 2023, when it climbed 3.82%.
• Innate Pharma's Accounts Payables stood at $32.7 million in 2021, then tumbled by 34.73% to $21.3 million in 2022, then dropped by 14.17% to $18.3 million in 2023, then fell by 6.58% to $17.1 million in 2024, then climbed by 2.37% to $17.5 million in 2025.
• The last three Accounts Payables figures came in at $17.5 million (Q4 2025), $13.6 million (Q2 2025), and $17.1 million (Q4 2024), per Business Quant data.